Nuvation Bio Inc
Company Profile
Business description
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
Contact
1500 Broadway
Suite 1401
New YorkNY10036
USAT: +1 332 208-6102
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
273
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,586.70 | 15.30 | 0.18% |
CAC 40 | 7,734.40 | 130.04 | -1.65% |
DAX 40 | 23,629.58 | 369.59 | -1.54% |
Dow JONES (US) | 41,603.07 | 256.02 | -0.61% |
FTSE 100 | 8,717.97 | 21.29 | -0.24% |
HKSE | 23,601.26 | 56.95 | 0.24% |
NASDAQ | 18,737.21 | 188.53 | -1.00% |
Nikkei 225 | 37,160.47 | 174.60 | 0.47% |
NZX 50 Index | 12,563.43 | 33.07 | -0.26% |
S&P 500 | 5,802.82 | 39.19 | -0.67% |
S&P/ASX 200 | 8,360.90 | 12.20 | 0.15% |
SSE Composite Index | 3,348.37 | 31.82 | -0.94% |